Clinical Trials
Our Network SELECT Southwest is currently conducting about 20 trials covering the different malignancies. Here you find an overview about our ongoing trials. If you have questions about a respective clinical trial or if you are interested in participating in the clinical trial please feel free to contact us.
Full text search in clinical trials
Larotrectinib (CONNECT1903)
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
rEECur
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcomaPalbociclib
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE® ) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORSONC201-108 (ACTION-Studie)
ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter StudyCD45RADLIHaplo
A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantationSIOP EPENDYMOMA II
An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymomaPerVision
Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas following standard treatmentLOGGIC/FIREFLY-2
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic TherapyGO42286 iMATRIX (Alectinib)
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS TumorsJ1S-MC-JP04 CAMPFIRE (Abemaciclib)
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing’s SarcomaEPCORE PEDS-1 (Epcoritamap)
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms.CPKC412A2218 (Midostaurin)
A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AMLAnti-CD19-ALL (Tafasitamab)
A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage LeukemiaSelumetinib Post-Authorization Safety Study (PASS)
Post-Authorisation Safety Study (PASS) of Pediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort StudyVyxeos® and Clofarabine (VyClo)
A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML (ITCC-092)FIREFLY-1
FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered, Recurrent or Progressive Low-Grade GliomaPembrolizumab (MK-3475, KEYNOTE-051)
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (KEYNOTE-051)METRO NB2012
Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma (METRO-NB2012)KEYNOTE-667 ( MK-3475-667, Pembrolizumab)
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)